Trial Profile
A randomized, placebo controlled, two-part study to evaluate the safety, tolerability, and pharmacokinetics of rolapitant in healthy volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 15 Oct 2018
Price :
$35
*
At a glance
- Drugs Rolapitant (Primary) ; Moxifloxacin
- Indications Chemotherapy-induced nausea and vomiting
- Focus Adverse reactions; Pharmacokinetics
- Sponsors TESARO
- 21 Apr 2016 New trial record
- 12 Mar 2016 Results (n=184) presented at the 117th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics.